Fig. 5: Restoration of calcium homeostasis and bone resorptive activity after allo-HSCT.

a Serum calcium of myelofibrosis patients before allo-HSCT (Pre, n = 123) and at 30 days (30 d, n = 120), 100 days (100 d, n = 112), as well as 1 year (1 y, n = 94) after allo-HSCT. b Phosphate of myelofibrosis patients before and after allo-HSCT (Pre, n = 113; 30 d, n = 49; 100 d, n = 28; 1 y, n = 24). c 25-hydroxyvitamin D (25-OH-D) of myelofibrosis patients before and after allo-HSCT (Pre, n = 96; 30 d, n = 59; 100 d, n = 63; 1 y, n = 77). d Parathyroid hormone (PTH) of myelofibrosis patients before and after allo-HSCT (Pre, n = 43; 30 d, n = 29; 100 d, n = 37; 1 y, n = 24). e Alkaline phosphatase (ALP) of myelofibrosis patients before and after allo-HSCT (Pre, n = 123; 30 d, n = 119; 100 d, n = 111; 1 y, n = 92). f Bone-specific alkaline phosphatase (Bone ALP) of myelofibrosis patients before and after allo-HSCT (Pre, n = 39; 30 d, n = 29; 100 d, n = 33; 1 y, n = 24). g Osteocalcin of myelofibrosis patients before and after allo-HSCT (Pre, n = 44; 30 d, n = 29; 100 d, n = 33; 1 y, n = 23). h Urinary deoxypyridinoline (DPD)/creatinine of myelofibrosis patients before and after allo-HSCT (Pre, n = 35; 30 d, n = 22; 100 d, n = 25; 1 y, n = 18). The median (center line, 50th percentile) and interquartile range (box edges, 25th– 75th percentile) with whiskers extending to the minimum and maximum values are depicted. Each data point is shown. The gray area indicates the reference range. In case of 25-OH-D, the gray line at 30 µg/l marks the threshold value for vitamin D insufficiency. Differences between the groups were calculated using Kruskal-Wallis H test with Dunn’s test (a–h). Exact p-values of the comparisons are displayed above the brackets and numbers in bold indicate statistical significance (p < 0.05). Source data are provided as a Source Data file.